HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at HC Wainwright reduced their FY2024 earnings per share estimates for 4D Molecular Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($2.89) for the year, down from their previous estimate of ($2.59). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.81) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($3.23) EPS.

Several other research analysts have also recently weighed in on the stock. Leerink Partners reiterated an “outperform” rating and set a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday. Chardan Capital restated a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald cut 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

4D Molecular Therapeutics Trading Up 10.1 %

Shares of NASDAQ FDMT opened at $8.83 on Monday. 4D Molecular Therapeutics has a 12-month low of $7.32 and a 12-month high of $36.25. The firm has a market capitalization of $408.21 million, a price-to-earnings ratio of -3.10 and a beta of 2.82. The firm has a 50 day moving average of $10.30 and a 200 day moving average of $17.03.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics in the third quarter worth $57,000. China Universal Asset Management Co. Ltd. boosted its position in shares of 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after acquiring an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in 4D Molecular Therapeutics during the third quarter valued at $108,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after acquiring an additional 3,026 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.